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ABSTRACT 
Individualization of therapy based on a person’s specific type of diabetes is one key element of 
a “precision medicine” approach to diabetes care. However, applying such an approach remains 
difficult because of barriers such as disease heterogeneity; difficulties in accurately diagnosing 
different types of diabetes; multiple genetic influences; incomplete understanding of 
pathophysiology; limitations of current therapies; and environmental, social, and psychological 
factors.  
 Monogenic diabetes, for which single gene mutations are causal, is the category most 
suited to a precision approach. The pathophysiological mechanisms of monogenic diabetes are 
understood better than those of any other form of diabetes. Thus, this category offers the 
advantage of accurate diagnosis of nonoverlapping etiological subgroups for which specific 
interventions can be applied. Although representing a small proportion of all diabetes cases, 
monogenic forms present an opportunity to demonstrate the feasibility of precision medicine 
strategies. 
 In June 2019, the editors of Diabetes Care convened a panel of experts to discuss this 
opportunity. This article summarizes the major themes that arose at that forum. It presents an 
overview of the common causes of monogenic diabetes, describes some challenges in 
identifying and treating these disorders, and reports experience with various approaches to 
screening, diagnosis, and management. This article complements a larger American Diabetes 
 
 Association effort supporting implementation of precision medicine for monogenic diabetes, 
which could serve as a platform for a broader initiative to apply more precise tactics to treating 






Diabetes mellitus is a common disease defined by hyperglycemia but including other metabolic 
disturbances. It can cause serious medical complications that reduce life expectancy and quality 
of life and poses a major public health challenge. The lifetime risk of developing diabetes is 
estimated to be at least one in three for people born in the United States (1). 
 Diabetes is commonly divided into categories (2). These include autoimmune-mediated 
type 1 diabetes leading to insulin deficiency; diabetes secondary to pancreatic injury; diabetes 
related to specific genetic disorders; and a broad category termed type 2 diabetes, in which 
insulin secretion is impaired and resistance to insulin’s actions is usually, but not always, 
present (3). Growing understanding of crucial differences in the pathophysiology underlying 
these distinct categories has the potential to improve outcomes by allowing for the application 
of specific therapeutic approaches (4). Such evidence-based individualization of therapy is a key 
component of the current movement toward “precision medicine” (5,6). 
 There are several barriers to implementing precision medicine in diabetes. These 
include disease heterogeneity; difficulties in accurately diagnosing different types of diabetes; 
multiplicity and variability of genetic influences; incomplete understanding of pathophysiology; 
limitations of current therapies; and environmental, social, and psychological factors that affect 
clinical management (7,8). Therefore, a step-wise approach is needed. 
 Monogenic forms of diabetes, for which single gene mutations are causal, are the ones 
best suited to more precise interventions. More than 50 genetic subtypes have been described 
in which the disease-causing mutation appears to be minimally affected by behavioral and 
environmental factors. Because the etiology of monogenic forms is known, their 
pathophysiological mechanisms are also understood better than those of other forms of 
diabetes. Although these disorders account for a relatively small proportion of all cases of 
diabetes, ranging from 1 to 5% in reports of pediatric and young-adult populations (9–14), they 
present an opportunity to demonstrate the feasibility of precise diagnostic and therapeutic 
strategies (15). Despite the demonstrated importance of making a correct diagnosis, it is 
estimated that at least 80% of all monogenic cases of diabetes remain undiagnosed (16).  
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In June 2019, the editors of Diabetes Care convened a group of experts to discuss this 
opportunity. The group was asked to consider the present scientific understanding of the main 
monogenic forms of diabetes, current experience with diagnostic and therapeutic approaches 
to the management of each of these, and the challenges to applying these insights at a 
population level. The American Diabetes Association and the European Association for the 
Study of Diabetes recently established the Precision Medicine in Diabetes Initiative to consider 
the potential for precision medicine in diabetes more generally (6), and this Diabetes Care 
Editors’ Expert Forum was intended to complement that initiative. This article summarizes the 
major themes that arose at the forum. 
 
MONOGENIC DIABETES: AN OVERVIEW  
 
Clinical Subtypes of Monogenic Diabetes 
An unusually strong genetic component causing diabetes in certain individuals was suspected 
decades ago by astute clinicians who observed two main clinical phenotypes that continue to 
be most suggestive of a possible monogenic cause: 1) onset of diabetes in neonates or infants 
(termed neonatal diabetes mellitus [NDM]) and 2) families with several generations of diabetes 
occurring in adolescents or young adults suggestive of an autosomal dominant pattern of 
inheritance (termed maturity-onset diabetes of the young [MODY]) (17). Other subtypes of 
monogenic diabetes include multisystem syndromes, severe insulin resistance (in the absence 
of obesity), and lipodystrophy (both full and partial). 
 
Evolving Classification Systems 
In the past three decades, the classification of monogenic diabetes disorders has evolved from 
one based on clinical characteristics (e.g., MODY) to one based on molecular genetics (e.g., 
glucokinase gene [GCK] status). This evolution has improved the robustness of diagnoses and 




 The order in which causative loci and genes were described in the literature was used 
originally in the nomenclature of MODY subtypes. Thus, a disorder involving the HNF4A gene 
was termed “MODY1,” one involving GCK was called “MODY2,” and so forth up to at least 
MODY14 at present (18). This approach has broken down, however, as more genes have been 
described. In some cases, new MODY numbers have been assigned without convincing rigorous 
evidence of causality (19), and in others, new genes involved in MODY have been described but 
not assigned a number (20).  
A more useful classification combines the standard abbreviation for the gene involved, 
followed by a term or abbreviation of the clinical phenotype (because the same gene can result 
in multiple phenotypes). Clinical phenotypes include MODY, PNDM (permanent NDM), TNDM 
(transient NDM), lipodystrophy; severe insulin resistance; and so forth. Examples of this 
combined nomenclature, then, are GCK-MODY, KCNJ11-TNDM, and PPARG-partial 
lipodystrophy (i.e., lipodystrophy caused by mutations in PPARG). When a clinical diagnosis is 
made but genetic testing has not been performed, the clinical classification can be used without 
an associated gene (e.g., MODY alone).  
 The term MODY itself can result in confusion with childhood-/young-adult–onset type 2 
diabetes, which is typically associated with marked obesity, unlike the familial monogenic form 
of diabetes for which the term was intended. Still, the term persists in the literature, and most 
diabetes care providers are familiar with it as a disease entity, even if they may not remember 
many other details. Hence, it is easiest to continue to use it as the clinical descriptor rather than 
inventing a new nomenclature. 
 
Common and Important Causes of Monogenic Diabetes 
The most common causes of monogenic diabetes (MODY and NDM) are listed in Table 1 and 
discussed in more detail below. 
 
GCK-MODY 
Nonprogressive hyperglycemia related to GCK, or GCK-MODY, is the most common cause of 
monogenic diabetes, with an estimated incidence as high in 1 in 1,000 individuals (21). It is 
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caused by heterozygous inactivating mutations in the enzyme glucokinase, which acts as the β-
cell glucose sensor (22,23). Metabolism of glucose initiated by GCK activity triggers the cascade 
of events leading to insulin secretion, but impairment of GCK activity causes an increase in the 
threshold glucose level required for insulin secretion to be initiated, while β-cell function is 
otherwise completely normal (24,25). The key role of GCK in hepatic regulation of glucose 
release and storage also results in defects in these processes. The overall result is mild fasting 
hyperglycemia, usually 97–150 mg/dL (5.4–8.3 mmol/L), and an A1C of ∼5.8–7.6% (40–60 
mmol/mol) (26). 
 This pattern is present from birth and remains remarkably stable over time, although 
there can be an age-related increase in A1C that is parallel to that seen in aging populations 
(27). Individuals are asymptomatic and are not diagnosed until incidental laboratory testing or 
routine screening reveals hyperglycemia, often as pediatric incidental hyperglycemia (28–30), 
during pregnancy, or during incidental illness (21,31,32).  
 Experts advise that no treatment is required, except possibly under certain 
circumstances during pregnancy in women with GCK-MODY (33,34). Nontreatment is advised 
because mild hyperglycemia is not sufficient to cause the microvascular or macrovascular 
complications associated with other forms of diabetes (26), and therapy does not lower glucose 
as it is regulated at the higher fasting level (35,36). This advice can sometimes be difficult for 
both people with GCK-MODY and earnest diabetologists to accept, yet the weight of the 
evidence showing the absence of diabetes complications and a lack of treatment response is 
clear. The urgent need to improve our recognition of this disorder is seen in the high 
percentage of individuals who are unnecessarily treated with a variety of medications before 
genetic diagnosis, for whom cessation of treatment usually has no effect on overall glycemia 
(35,37,38). 
 
HNF1A-MODY and HNF4A-MODY  
HNF1A-MODY is the most common cause of symptomatic, treatment-requiring MODY (39). Less 
common mutations in another β-cell transcription factor (HNF4A) have a similar clinical 
presentation and treatment requirement (40). These genes encode transcription factors 
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present in many tissues. Although originally named as hepatocyte nuclear factors after being 
identified as transcription factors in a liver cDNA library, these genes play more important roles 
in the β-cell and are also expressed in multiple other organs such as the kidney. 
 Individuals with either HNF1A-MODY or HNF4A-MODY usually have an excellent 
glucose-lowering response to low doses of inexpensive oral sulfonylurea medications, but there 
are key differences in other associated clinical features of these two subtypes. Before a genetic 
diagnosis, patients are often treated with a variety of less-effective medications such as 
metformin or insulin, and switching to a sulfonylurea is not only cheaper, but also tends to 
improve glycemic control (41–44). The response to sulfonylurea treatment can be so dramatic 
that hypoglycemia can cause a provider to switch to a different treatment, when in fact this 
response could be recognized as a reason to adjust dosing and pursue genetic testing. 
 A reduction in HNF1A regulation of sodium–glucose cotransporter 2 (SGLT2) levels in the 
kidney results in glycosuria despite near-normal blood glucose levels (45). This response means 
that glycosuria can be an early marker of children who have inherited an HNF1A mutation (46). 
Given the effects of HNF1A on SGLT2 expression, caution should be observed in administering 
SGLT2 inhibitor medications to such individuals (46). 
HNF4A-MODY has a similar diabetes phenotype to HNF1A-MODY with one clinically very 
important difference: fetuses and newborns with an HNF4A mutation have excessive insulin 
secretion. The increased fetal insulin secretion results in a marked increase in birth weight 
(~800 g) and a very high risk of macrosomia even when a fetus has inherited from the father 
(47). The neonatal hyperinsulinism can result in persistent and prolonged hypoglycemia in some 
patients (47,48). The management of HNF4A-MODY in pregnancy is discussed later in this 
article. The mechanisms underlying neonatal hyperinsulinemia but subsequent diabetes 
resulting from reduced β-cell function in HNF4A remain unexplained. 
 
HNF1B-MODY 
HNF1B-MODY is typically characterized by renal cysts and diabetes but can feature 
developmental anomalies in multiple systems (49). This form of diabetes typically starts in 
adolescence or early adulthood, is usually insulin-requiring, and may be insulin-dependent 
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because the etiology is a reduced number of β-cells in development. Frequently, there is also 
reduced pancreatic exocrine function, which may require treatment. Reduced pancreatic tail 
size or low fecal elastase can aid diagnosis of exocrine pancreatic insufficiency. Although renal 
cysts are typical, multiple subtypes of developmental kidney disease have been described. 
HNF1B-MODY is the most common genetic etiology of childhood kidney disease, accounting for 
20–30% of cases (49). 
 
KCNJ11-NDM and ABCC8-NDM  
Activating heterozygous mutations in either gene encoding the subunits of the β-cell KATP 
channel (KCNJ11 or ABCC8) are the most common cause of PNDM and a major cause of TNDM 
(50–55). Mutated channels maintain membrane hyperpolarization even in the face of extreme 
hyperglycemia, but treatment with high doses of a sulfonylurea can overcome these defects, 
enabling transition off of insulin (56) and restoring meal-stimulated insulin secretion (57) with 
minimal hypoglycemia (58). Excellent glycemic control commonly persists even after >10 years 
of treatment (59). 
 The clinical phenotype is correlated with the severity of mutation, with more damaging 
variants also causing a spectrum of neurodevelopmental disabilities that can be at least 
partially ameliorated by early initiation of sulfonylurea treatment once a genetic diagnosis is 
revealed (60–62). More mildly activating mutations are a common cause of TNDM (ABCC8 more 
often than KCNJ11) or may present as a rare form of MODY in individuals or family members 
who are not known to have had neonatal hyperglycemia but later in life develop MODY-like 
diabetes that is also usually responsive to a sulfonylurea (63,64). Other rare causes of NDM 
from KATP mutations include bi-allelic mildly activating mutations (usually homozygous), as well 
as compound heterozygous mutations, in which one is activating, and the other is a loss-of-
function (LOF) variant (65). However, homozygous LOF variants in either gene cause congenital 
hyperinsulinism (66).  
 
Imprinted Locus at Chromosome 6q24 
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Overexpression of maternally methylated genes at chromosome 6q24 is the most common 
cause of TNDM, in which the diabetes spontaneously resolves within the first year of life but 
usually recurs in adolescence or young adulthood (67). When diabetes recurs, clinicians must 
recognize the significance of the TNDM history because these patients will often respond to 
oral medications and not require insulin (68).  
 
INS-NDM and INS-MODY 
With certain subtypes of monogenic diabetes, a genetic diagnosis may not lead to changes in 
treatment of diabetes but could still allow for a precision-based approach. For example, 
heterozygous mutations in the proinsulin gene (INS) are the second most common cause of 
PNDM, stemming from a progressive loss of β-cell functional capacity resulting from 
accumulation of misfolded proinsulin protein (69). Although treatment is currently limited to 
insulin, minimizing the stimulus for excessive production of the mutated protein by minimizing 
hyperglycemia through early intensive insulin management may allow for slowing of the 
progressive loss of β-cell function and better long-term outcomes (70). 
 Recessive nonsense or promoter INS variants preventing or greatly reducing insulin 
secretion also cause PNDM or TNDM (71,72). Rare INS variants also cause a form of MODY 
through distinct mechanisms such as reduced binding at the insulin receptor, but the best 
therapeutic options for these rare patients have not yet been established (73,74).  
 
Less Common Causes of Monogenic Diabetes  
Monogenic diabetes can result in multisystem syndromes that are usually congenital and hence 
result in neonatal diabetes (50,75) but can also result in a later onset of diabetes. The most 
common multisystem syndromes that present later in life are HNF1B (discussed earlier), 
mitochondrial diabetes, and Wolfram syndrome. These syndromes frequently present with 
diabetes which may not be recognized as a first manifestation of a multisystem disease. 
 Cardinal features of mitochondrial diabetes syndromes, most commonly caused by 
m.3243A>G mutation, include maternally inherited diabetes (typically diagnosed in the third or 
fourth decades of life), sensorineural deafness (typically diagnosed before the diabetes), and 
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several other possible problems such as renal manifestations, cardiomyopathy, myopathy, and 
central neurological features (76). Wolfram syndrome is a rare, severe, multisystem condition 
characterized by insulin-dependent diabetes (diagnosed in the first decade of life), optic 
atrophy, diabetes insipidus, and sensorineural deafness. It is usually caused by recessive 
mutations in WFS1 (77).  
 Other subcategories of monogenic diabetes include a growing list of genes causing 
monogenic autoimmune syndromes in which diabetes is a common feature (78). 
Lipodystrophies and other syndromes of severe insulin resistance often go unrecognized as 
clinically distinct from type 2 diabetes even though optimal management may entail vastly 
different therapeutic approaches (79,80). The heterogeneity of phenotypic presentation and 
age of onset can hinder recognition of such patients as candidates for genetic testing, but even 
if the diabetes can only be treated with insulin a correct diagnosis can still guide monitoring and 
treatment of associated features, clarify the long-term prognosis, and lead to testing in family 
members.  
 
CHALLENGES AND OPPORTUNITIES IN DIAGNOSIS AND TREATMENT 
 
Challenges in Diagnosis and Management 
The presence of a monogenic form of diabetes should be considered when a patient does not 
seem to fit with the more common presentations of type 1 or type 2 diabetes. Decades of 
research on different populations have shown that any stringently defined set of features will 
be too restrictive to identify all people who carry a highly penetrant genetic variant. Such 
criteria, originally associated with the research by Stefan S. Fajans on MODY (17), have typically 
included onset before the age of 25–35 years, lack of insulin dependency (as shown by 
treatment or C-peptide measurement), absence of obesity or other signs of insulin resistance, 
and dominant inheritance over several generations. The absence of pancreatic islet-specific 
autoantibody titers associated with type 1 diabetes has now become another important 
measure. No approach will be sensitive enough to accurately detect every case or specific 
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enough to ensure that genetic testing is not performed on patients who turn out not to have a 
monogenic diagnosis.  
 
Selecting Appropriate Individuals for Genetic Screening 
Because no combination of clinical, historical, and biomarker information can reliably identify 
all cases, there must be a balance between the desire to test more often (even when the 
chance of a positive result is very low) and the need to control costs (by restricting testing to 
selected groups). In the absence of clear guidelines, decisions on testing rest with individual 
clinicians. This dilemma occurs especially in youth or young-adulthood, when the more 
common forms of monogenic diabetes are most likely to become apparent. Some patients who 
are unlikely to have MODY are tested, whereas many who are very likely to have MODY are not. 
 There are also barriers to making a diagnosis for certain individuals who are very likely 
to have MODY, such as those with diabetes who are first- or second-degree relatives to people 
with known monogenic diabetes. Evaluation of close relatives has not been a priority in 
diabetes care and can be challenging, especially when they receive health care from a different 
medical team or live far away. 
 
Accessing Genetic Testing 
Difficulties in arranging for genetic testing can include a lack of availability and high costs, even 
when testing is partially covered by insurance plans. In most industrialized countries, molecular 
genetic testing for MODY is available, but in many regions throughout Asia and Africa, samples 
must be sent to distant laboratories outside of the patient’s country of residence. 
 Inequities in access may arise when such testing is not provided by a state health care 
system or not covered by private insurance companies. The cost of genetic testing, like that of 
other technology-related services, is likely to decline but a significant decrease has not yet 
occurred. In systems with commercial payers, cumbersome authorization processes and high 
direct costs to patients can influence whether testing is done. Even in government-funded 
health care systems, restrictions due to limited resources dictate that testing be performed only 




Ensuring the Quality of Testing and Interpretation of Results 
Genetic testing would seem to be a robust procedure, but there are troublesome issues with 
both the methods used and interpretation of the findings. Many laboratories have offered 
testing for only a few of the most common genetic disorders. However, improvement in testing 
methods, particularly the advent of multiple gene sequencing, now allows more subtypes of 
monogenic diabetes to be assessed with a single test. 
 Recent studies have demonstrated the importance of comprehensive testing. One used 
a population-based approach to screen all non-neonatal patients diagnosed with diabetes at 
<30 years of age and found that up to 18% of those with monogenic diabetes had subtypes 
other than GCK, HNF1A, and HNF4A (81,82). These rarer but clinically significant forms include 
ABCC8/KCNJ11 (which respond to sulfonylurea treatment), HNF1B (diabetes with renal cysts 
and/or other genitourinary defects and other associated features) (49), and m.3243A>G (the 
most common mitochondrial mutation causing maternally inherited diabetes and deafness 
[76]).  
 Errors in the interpretation of sequencing are also common in diagnostic laboratories 
with limited experience with monogenic diabetes, and when the clinical presentation of 
patients and the pre-test likelihood of a monogenic diagnosis are not considered (19). The 
increase in the number of genes assessed has exacerbated problems of interpretation. With the 
more common MODY genes, mutations frequently lead to haploinsufficiency, and causality of 
novel variants is therefore easier to predict. For genes including PDX1, CEL, ABCC8, KCNJ11, and 
INS, in which a heterozygous nonsense mutation causing haploinsufficiency does not result in 
the diabetes phenotype, more sophisticated interpretation is needed. In contrast, certain 
missense mutations may be causal, whereas other missense variants and protein-truncating 
variants may be benign. Other genes being tested do not actually meet robust criteria for 
causing monogenic diabetes (83). These issues were reviewed in a recent commentary by Ellard 
et al. (19). 
 Assessment of allele frequency in people not selected for disease in databases such as 
gnomAD (84) has helped to rule out alleles that are too frequent to cause MODY (1 in 60,000 
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alleles or 1 in 30,000 people), and several variants previously published as mutations can now 
be excluded. Despite the availability of this information, the lack of widespread understanding 
results in common polymorphisms still being reported as causal mutations.  
In short, there is still a long way to go in achieving consistent, high-quality interpretation 
of genetic testing. Fortunately, efforts are underway to address these problems. For example, 
all laboratories should be encouraged to take part in quality assurance programs such as the 
European Molecular Genetics Quality Network MODY Group (85). The National Institutes of 
Health–supported Clinical Genome Resource (86) includes a long-term effort to bring together 
disease-specific clinical and genetic experts to evaluate the evidence for gene-disease 
relationships and to establish the likelihood that known variants are causal or benign, using 
recently established American College of Medical Genetics and Genomics/Association for 
Molecular Pathology guidelines (87). The Monogenic Diabetes Variant Curation Expert Panel is 
developing a systematic process for reviewing pathogenicity and submission to ClinVar (88).  
 Even as reporting of genetic testing improves the clinical significance of reports may not 
be understood by medical providers, even those who are diabetes specialists. This occurs most 
often when “variants of uncertain significance” (VUS) are reported, leaving the ordering 
providers to draw their own conclusions about possible causality. Whereas some laboratories 
thoroughly review and report all possible evidence, others may report a variant as a VUS if their 
review is less complete. Some laboratories lack a standard process for obtaining clinical data 
that might improve the relevance of their reported conclusions. 
 
Taking Appropriate Clinical Action 
Additional problems arise when a genetic diagnosis is established but appropriate changes of 
clinical management are not made. Many diabetes health care professionals do not have 
experience with genetic subgroups, and genetic reports often do not provide clinical guidance. 
Failure to recognize the implications of a diagnosis of GCK-MODY can result in initiation of 
glucose-lowering treatment which will be ineffective (Table 1) (35). Similarly, insulin therapy 
may be prescribed unnecessarily for HNF1A-MODY, which is highly responsive to sulfonylurea 
therapy (43). Informed therapeutic decisions are particularly needed in the setting of pregnancy 
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accompanying GCK-MODY. Moreover, clinicians should be aware that not all patients in specific 
monogenic diabetes subgroups will respond well to what is considered optimal therapy, and 
those who respond initially may require changes to therapy later (89).  
Beyond glycemic control, appropriate management of monogenic diabetes also can 
include examining other organs that may be affected. Examples include renal function with 
HNF1B-MODY (49) and echocardiographic or electrocardiographic changes due to 
cardiomyopathy associated with mitochondrial mutations that cause maternally inherited 
diabetes and deafness (76).  
 
Opportunities in Diagnosis and Management 
 
Improving Recognition of Potential Monogenic Diabetes Patients  
Understanding which individuals are most likely to have a monogenic etiology is centrally 
important. One consideration in genetic screening is the age at which a patient is diagnosed 
with diabetes. Other considerations include clinical features and laboratory test results. 
 
Diagnosing Monogenic Neonatal Diabetes 
Identifying monogenic NDM is relatively easy because the only alternative diagnosis is type 1 
diabetes, which is very rare before the age of 6 months. Using a cutoff age of 6 months 
identifies a group of patients in which at least 82% have an identifiable form of monogenic 
NDM (50). There is absolutely no doubt that every patient diagnosed in the first 6 months of life 
should be genetically tested. 
 It is uncertain whether testing patients diagnosed with diabetes between 6 and 12 
months of age is economically justified. The answer will depend on the frequency of pathogenic 
KATP channel mutations. Correct diagnosis of such mutations, allowing for inexpensive 
treatment with sulfonylureas and improved long-term glycemic outcomes, may make a policy 
of testing cost-saving as long as at least 3% of those screened have treatable defects (90). One 
study found that 4% of patients presenting between the ages of 6 and 9 months had KATP 
channel–related NDM, suggesting that a policy of testing up to 9 months of age likely remains 
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cost-saving (91). Very few KATP channel mutation cases have been reported as being diagnosed 
after 9 months of age (92,93), and such cases have not been found in systematic surveys of this 
age-group (91). Thus, at present, it is not cost-effective to test after 9 months of age, but this 
cut-point may change with future studies.  
 
Distinguishing MODY From Type 1 Diabetes and Type 2 Diabetes 
Diagnostic criteria must be able to discriminate MODY from both type 1 diabetes and type 2 
diabetes. Efforts to do so are complicated by the fact that clinical features differ among the 
common subtypes of MODY. Selection of appropriate patients for genetic testing must consider 
a combination of clinical considerations and laboratory tests, with the latter primarily being 
used to exclude type 1 diabetes. 
 Although no algorithm will be perfect, the MODY probability calculator 
(https://www.diabetesgenes.org/mody-probability-calculator), which estimates the likelihood 
of a patient having MODY based on clinical criteria, is a robust and widely used method of 
assessing the clinical likelihood of genetic etiology (94). Further refinement and validation for 
different populations in different countries and/or clinical settings should yield reasonable 
estimates of the probability that testing will reveal a monogenic diagnosis. Health systems 
could consider using such tools to establish policies allowing for genetic testing in patients 
whose probability of having an underlying monogenic cause meets an established cost-
effectiveness threshold, while allowing for exceptions based on individual circumstances.  
 
Establishing the Cost-Effectiveness of Genetic Testing for MODY 
Distinguishing certain forms of MODY from both type 1 and type 2 diabetes can result in 
significant treatment differences and improvements in outcome that have the potential to 
greatly reduce costs. One study modeled the potential cost differences of distinguishing MODY 
from type 2 diabetes based on the assumption of improved glycemic control using sulfonylurea 
therapy for HNF1A-/HNF4A-MODY and no treatment for GCK-MODY (95). This analysis 
suggested that a policy limiting testing to individuals who have at least a 6% chance of having 
MODY will be cost-effective. If the criteria used can identify a group of patients in which 30% 
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will have a monogenic cause, genetic testing will be cost-saving. Interestingly, genetic testing of 
all patients with type 2 diabetes diagnosed at <40 years of age could potentially be cost-
effective if the cost of testing were reduced to <$700 (95).  
A more recent study used real-world data from several studies of pediatric diabetes to 
model the cost-effectiveness of systematic biomarker screening and genetic testing of patients 
diagnosed with diabetes between the ages of 10 and 20 years who are C-peptide–positive and 
anti-islet autoantibody–negative (96). Based on the assumption of improved glycemic control 
with sulfonylurea therapy (in most cases instead of insulin) for those found to have HNF1A-
/HNF4A-MODY and cessation of all treatment in those found to have GCK-MODY, the model 
suggested that such a screening approach would be cost-saving, and the savings would increase 
for every additional family member who could be identified. 
A recent study based on data from the United Kingdom (97), including data from the 
UNITED (Using pharmacogeNetics to Improve Treatment in Early-onset Diabetes) study (81), 
further assessed the potential of systematic screening of adults with diabetes. The analysis was 
based on C-peptide and autoantibodies in insulin-treated patients diagnosed with diabetes at 
<30 years of age. Health economic modeling established that an algorithm-based strategy using 
these biomarkers, together with the MODY probability calculator, saved ~£100–200 ($123–246 
USD) per person tested over a lifetime (97). Based on the population of England and Wales, 
applying this approach in those with diabetes diagnosed before the age of 30 years who are 
currently <50 years of age would be predicted to save the health care system £20–40 million 
($25–49 million USD).  
 
Identifying MODY in Pediatric and Young-Adult Age-Groups 
The main alternative diagnosis in the pediatric age-group is type 1 diabetes. Cases of type 2 
diabetes usually stand out because of their obesity, parental family history, high-risk 
racial/ethnic group, or some combination of these characteristics. Many pediatric patients with 
diabetes are treated with insulin immediately, even when they have modest hyperglycemia, 
making it difficult to assess their underlying β-cell function. Even if C-peptide measurement 
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confirms that a patient has significant endogenous insulin secretion, type 1 diabetes in an early 
stage or honeymoon period remains a possibility. 
 Testing for multiple islet autoantibodies that are present in type 1 diabetes can help 
greatly. These include IA-2A (islet antigen 2 autoantibodies), IAA (insulin autoantibodies), GADA 
(GAD autoantibodies), and ZnT8A (zinc transporter 8 autoantibodies). Individuals with titers 
greater than the 97.5th percentile for one or more autoantibodies do not need to be tested for 
MODY (11,13). However, 12–15% of individuals with pediatric diabetes are anti-islet 
autoantibody–negative at the time of diagnosis, the majority of whom have autoimmune 
diabetes (11,13); this proportion decreases with repeat testing (98). Additionally, GADA can be 
positive in 1–2% of people without diabetes (99). 
 Beyond autoantibody status, two other key factors that raise the likelihood of a 
monogenic disorder are an A1C <7.5% at diagnosis, and a parental history of diabetes (13).  
 
Identifying MODY in Middle-Aged Adults 
Although MODY can present later in life, the vast majority of cases involve diabetes diagnosed 
before the age of 35 years. Individuals diagnosed after the age of 40 years should only 
exceptionally be tested; the person in a family who was diagnosed at the youngest age with 
noninsulin-dependent diabetes should be tested first. In patients <40 years of age who are not 
treated with insulin, the major differential diagnosis is familial type 2 diabetes, with the key 
discriminatory factors for MODY being low BMI and earlier age of diagnosis, as is well assessed 
by the MODY probability calculator (94). For patients <40 years of age who start insulin therapy 
immediately upon diagnosis, the main differential diagnosis is type 1 diabetes, and testing for 
islet autoantibodies, C-peptide levels, or both can help to discriminate, along with clinical 
features.  
 
Elucidating the Epidemiology of Monogenic Diabetes 
Population-based intervention for any disorder requires information on its epidemiology. 
Defining the epidemiology of monogenic diabetes is difficult because there have been few 
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population-based studies, and those done have been mostly in populations that are 
predominantly white and of European origin. 
 PNDM is one of the better-studied categories of monogenic diabetes. In most 
population studies in high-income countries with a low prevalence of consanguineous 
marriages, its prevalence is 1 in 100,000–200,000 live births, and most cases are heterozygous, 
with ~80% being de novo mutations (50). Low-income countries have a much lower frequency 
of recognized cases. In regions having high rates of consanguineous marriage, the prevalence of 
PNDM is much higher (~1 in 20,000–40,000 live births), and recessive causes are found in the 
majority of cases (50).  
 The prevalence of MODY has been best investigated in population-based studies of 
pediatric cases in Europe and the United States, with prevalence rates ranging from 0.6 to 6.3%, 
as reviewed by Shepherd et al. (89). A major cause of variation in prevalence is how many 
individuals with GCK mutations are identified, which has ranged from 20% of MODY when there 
is a MODY prevalence of 0.6% (100) to 75% of MODY when there is a MODY prevalence of 6.3% 
(101). GCK mutations were more prevalent when pediatric patients with persistent incidental 
hyperglycemia were included as well as patients diagnosed with diabetes. 
 There have been few systematic epidemiological studies of adults because of the large 
numbers involved. The only study of which we are aware is the previously mentioned UNITED 
study (81). This study was conducted in two regions of the United Kingdom, where all patients 
who had been diagnosed with diabetes at <30 years of age who were still <50 years of age were 
genetically screened if they did not have a low C-peptide level or high-titer pancreatic 
autoantibodies. Using this approach, 3.6% of this young-onset group had monogenic diabetes. 
 Because systematic studies of monogenic diabetes have focused on populations of 
people who are relatively younger and/or known to have features suggestive of a monogenic 
cause, the actual population-wide prevalence over the full range of ages remains uncertain.  
 





The study of monogenic diabetes is a relatively new field. At present, monogenic diabetes is not 
generally diagnosed via systematic population screening, but rather by investigation of cases 
referred by individual physicians based on a likely clinical presentation. This approach is still 
missing as many as 80% of monogenic diabetes cases, which are instead being misdiagnosed as 
type 1 or type 2 diabetes. (16,102). 
 Studies of physician referrals to specialist centers for genetic diagnosis have shown that 
there is a marked degree of regional variation in referral for (and therefore in diagnosis of) 
monogenic diabetes (16,102). Factors that contribute to this problem include differences in 
awareness of monogenic forms of diabetes among clinicians and differences in access to 
appropriate screening and genetic testing services. The existence of specialist networks and the 
geographical distribution of expert centers have clear effects on identification of new cases 
(16,101). For these reasons, the reported prevalence of monogenic diabetes as a percentage of 
all cases varies widely among different regions and countries. 
 A more systematic screening approach using a predefined protocol to examine 
consecutive pediatric cases was reported by an Italian group who conducted a retrospective 
analysis (101). This study was conducted through a network of pediatric centers providing good 
coverage and access throughout Italy, and followed a sequence of investigations from type 1 
diabetes–associated autoantibodies through to genetic testing based on presenting “metabolic 
phenotype.” This method identified a higher proportion of monogenic cases, 6.3% of the total 
(101), than has been reported elsewhere in similar age groups. 
 Education of clinical providers has been shown to greatly improve the effectiveness of 
the physician-based approach to the diagnosis of monogenic diabetes. In one ongoing project, 
the monogenic diabetes specialist team at the Royal Devon and Exeter National Health Service 
Foundation Trust and University of Exeter Medical School trained a cohort of 52 diabetes nurse 
specialists across the United Kingdom to serve as genetic diabetes nurses (103). This project has 
been highly effective at spreading the necessary clinical expertise from specialist testing centers 
to routine clinical care settings. Such a nurse-led approach to clinician education seems ideal for 





Systematic Population-Based Screening 
An alternative approach used in the UNITED trial (81) is systematic population-based screening 
to identify young patients for possible MODY sequencing, using low C-peptide and positive 
autoantibodies to exclude likely type 1 diabetes. This approach has been shown to be highly 
effective and cost effective (97). Applied at scale, it should ensure that there are no inequities 
in screening and diagnosis of monogenic diabetes in the population tested. 
 A similar strategy of C-peptide testing in individuals with >3 years’ duration of assumed 
type 1 diabetes and autoantibody testing at diagnosis, with monogenic gene sequencing then 
performed in those who are autoantibody-negative or have a persistently robust C-peptide 
level, is now being implemented in Scotland, making it the first country to implement 
population-wide testing for monogenic diabetes. 
 
Screening in the Pediatric Population 
Making a correct diagnosis of MODY in pediatric diabetes is important because these patients 
will spend almost their whole life living with diabetes, and increasing attention is directed to 
this problem. However, the correct diagnosis often is made years after an incorrect initial 
diagnosis, when assumed type 1 diabetes fails to progress. Making a MODY diagnosis close to 
the initial diagnosis of diabetes is a priority. 
 Currently, recognition of possible MODY cases is based on clinical features at follow-up 
rather than on any sort of assessment at the time of diabetes diagnosis. There is clear evidence 
of the need for systematic testing; the multicenter SEARCH for Diabetes in Youth study in the 
United States (11) showed the HNF1A, HNF4A, and GCK mutations accounted for 1.2% of 
diabetes cases in the pediatric population, but the vast majority of these patients with MODY 
were misdiagnosed and inappropriately treated with insulin. Screening procedures or 
algorithms based on islet autoantibodies that are reliable discriminatory factors at diagnosis 
(104) could be used to direct genetic testing for MODY sooner. Using such protocols would 




 Comprehensive autoantibody testing close to the time of diagnosis to guide testing for 
MODY has been performed in pediatric populations in a large multicenter study in the United 
States (11) and in national studies in Sweden (13) and Norway (100). Testing for MODY was 
systematically performed in the 12 to 15% in whom islet antibodies were not detected. The 
overall prevalence of MODY in these three studies was 0.8–1.2%. No cases were reported when 
patients were autoantibody-positive (13). In these studies, the absence of autoantibodies was 
the strongest predictor of MODY in these populations, being more discriminatory than any 
clinical criteria. Because MODY is detected in 7–15% of all autoantibody-negative children, 85–
93% of these patients do not have MODY; the majority have type 1 diabetes, but some have 
type 2 diabetes, and this proportion varies depending on the population studied (11). 
 In the most comprehensive study at diagnosis to date (13), individuals with MODY had 
lower random plasma glucose and A1C levels than those without MODY and did not present 
with diabetic ketoacidosis. These indications of severity of presentation discriminated better 
than the other good predictor—a parental history of diabetes. Using this information could 
reduce the number of autoantibody-negative patients who need testing for MODY near the 
time of diabetes diagnosis in pediatric populations, but this reduction will be at the cost of 
missing some cases.  
 
Diagnosis and Management of MODY in Pregnancy 
MODY patients, especially those with GCK-MODY, are often identified during pregnancy. 
Monogenic disorders account for 1–2% of all cases of diabetes diagnosed during pregnancy, 
with GCK-MODY being found in one in three patients with a fasting glucose ≥100 mg/dL (5.5 
mmol/L) and normal weight (BMI <25 kg/m2) (21). It is important to correctly identify patients 
with GCK-MODY because its clinical course and management differ substantially from those of 
other types of diabetes in pregnancy.  
 In GCK-MODY, the primary determinant of fetal growth is the fetal genotype, with 
affected fetuses having normal birth weight and unaffected fetuses being ~500–600 g heavier 
than normal (33). Fetal genotype is not usually known, although an exciting new development 
is the use of noninvasive testing using cell-free DNA in maternal blood to assess whether a fetus 
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is affected (105). In the absence of cell-free DNA testing, serial fetal ultrasound measurements 
can help determine likely fetal genotype. If accelerating fetal abdominal circumference—a sign 
of macrosomia—is present on serial ultrasounds, it can be assumed that the fetus does not 
have the GCK mutation. Insulin therapy is usually recommended to reduce the risk of 
macrosomia, and delivery could be induced at 38 weeks. However, well designed studies have 
not proven that this approach leads to fewer complications, whereas insulin treatment may be 
associated with episodes of hypoglycemia, including severe hypoglycemia (33,34). If serial 
ultrasounds show normal fetal growth, the fetus has probably inherited the GCK mutation and 
will have an elevated glucose set-point similar to that of the mother. In that setting mild 
maternal hyperglycemia is desired (31,106), and treatment is not indicated and may be harmful 
by resulting in low birthweight (34). 
 It is crucial to recognize HNF4A-MODY in pregnancy because fetuses that inherit the 
HNF4A mutation will be ~800 g heavier than those that do not inherit the mutation. This 
tendency to gain weight, especially if combined with maternal hyperglycemia, can result in 
massive macrosomia (>5 kg) which can cause severe fetal and maternal complications (47). 
Thus, repeated ultrasound scans are needed, with early delivery if they reveal evidence of 
excessive fetal growth (47). It is also important to monitor the fetus carefully when the father 
has MODY, even though the mother is unaffected and has normal glucose levels, because if the 
fetus is affected the risk of macrosomia is as high as or higher than in conventional gestational 
diabetes (47). 
 The excessive fetal insulin secretion caused by HNF4A mutation that leads to 
macrosomia can also result in prolonged and severe neonatal hypoglycemia. For this reason, a 
pediatrician should be present at delivery, and urgent HNF4A testing for the specific mutation 
in the fetus should be performed rapidly. The emerging method of determining fetal mutation 
status using cell-free DNA from the mother allows for prediction of fetal outcome before 
delivery without relying on indirect evidence from maternal ultrasound scans (105). 
 In HNF1A-MODY and HNF4A-MODY, as in all other forms of diabetes during pregnancy, 
maternal glycemic control is a major determinant of fetal outcomes. The challenges in both 
MODY subtypes are twofold: uncontrolled hyperglycemia during the first trimester, the time of 
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organogenesis, and a risk of macrosomia and neonatal hypoglycemia accompanying 
sulfonylurea therapy in the third trimester (107). Therefore, different treatment strategies have 
been proposed: either stopping sulfonylurea therapy before pregnancy and switching to insulin 
or continuing sulfonylurea in the preconception period and early pregnancy and then switching 
to insulin in the second trimester (108). The latter option has been suggested for patients with 
excellent glycemic control on sulfonylureas prior to pregnancy. Glyburide has been the most 
extensively studied sulfonylurea in pregnancy and is therefore recommended as the agent of 
choice (107). 
 In general, however, studies of pregnancy affected by monogenic diabetes are scarce, 
and data from prospective studies are needed to better define the need for and timing of 
insulin treatment during pregnancy (31,106). 
 
SUMMARY AND A WAY FORWARD  
The promise of precision medicine is based on the individual or groups of individuals. The 
approach incorporates aspects of family history (genetics), lifestyle, and environment, such that 
the health care provider can customize interventions, diagnostics, and therapeutics to permit a 
healthier life for the patient and reduce health care utilization and costs. In diabetes, there are 
numerous forms of the disease at presentation, ranging from monogenic (involving single gene 
mutations) to those with complex etiologies (such as autoimmune type 1 diabetes) that require 
exogenous insulin for survival, to the most common form (type 2 diabetes) that itself results 
from dysregulation of multiple, incompletely understood metabolic processes.  
Monogenic diabetes is currently the form of diabetes that is most relevant for the 
application of precision medicine in terms of diagnosis and treatment. However, the growing 
understanding of monogenic diabetes alone will not lead to much change in clinical practice. 
Practical application of this information requires several additions to diabetes management as 
it occurs in most places. It is also important to recognize that the distribution of various forms 
of monogenic diabetes relative to type 1 diabetes or type 2 diabetes may differ across global 
populations. As a preliminary proposal, this expert panel suggests that three programs are 
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needed to accomplish and sustain population-based diagnosis and management of these 
disorders.  
1. A regional infrastructure 
There should be basic agreement on definitions and guidelines developed by 
professional societies or governmental agencies. The American Diabetes Association’s 
Precision Medicine in Diabetes Initiative (6), including this Diabetes Care Editors’ Expert 
Forum, represents a step in this direction. Regional collection, storage, and 
management of data will be necessary. Such efforts are being undertaken in some 
countries in the form of disease-specific registries, but prospective management of data 
is insufficient in most locations. Depending on the size and geography of a given region, 
one or multiple specialized centers are needed. Ongoing financial support is necessary, 
and the case for providing it must be made based on the results of cost-effectiveness 
studies. 
  
2. Specialized expertise 
Regional centers must be staffed by adequately trained professionals who are expert in 
the epidemiologic, genetic, and clinical aspects of diabetes. These specialty groups could 
manage the data, oversee laboratory methods, train personnel, and interact with clinical 
providers. Primary care providers need and will continue to need education and 
consultative support regarding individual cases, all of which can be provided by 
specialized diabetes centers. 
  
3. Research toward population-based management of other forms of diabetes 
The infrastructure and expert center networks might be expected, over time, to expand 
their activities to study of the genetic factors underlying other forms of diabetes. At 
present, combined clinical and genetic risk scores are in development to assess risks of 
developing type 1 diabetes and type 2 diabetes and to predict individuals’ need for and 
responses to various pharmacotherapies. In the future, clinical investigation of various 
kinds could be carried out efficiently through these centers of expertise. Ongoing 
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screening for and treatment of individuals with monogenic disorders will naturally 
accrue data that bear on the population-based management of all forms of diabetes. It 
may be feasible to develop prospective trials of new methods of prevention or 
treatment of the more common types of diabetes using the same infrastructure and 
personnel.  
  
 It should be recognized that all forms of diabetes evolve over time for every affected 
individual. The pathophysiology and appropriate treatments change over time and can be 
altered by the appearance of other comorbid conditions, complications, changes of lifestyle or 
environmental factors, and patients’ perceptions of their disease. Therefore, services provided 
by the systems just described are relevant not just at the time of screening and diagnosis, but 
longitudinally throughout the life span of each individual. 
 In summary, we suggest that a systematic approach to screening for and appropriately 
treating monogenic diabetes could establish a platform on which to base a broader initiative 
toward precision treatment of diabetes in general. For the present, it seems appropriate to go 
for the low-hanging fruit: the easily diagnosed cases of monogenic diabetes for which specific 
therapeutic approaches are already established, yet all too seldom correctly applied.  
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TABLE 1. Clinical Implications of Some Common and Important Causes of Monogenic Diabetes 





AR: GCK-NDM (very rare) 
Reduced function of glucokinase enzyme 
raises set-point for insulin secretion that is 
otherwise normal; high population 
prevalence of causal variants (~1 in 1,000) 
No treatment needed for most 
patients (except possibly during 
pregnancy) 
HNF1A AD: HNF1A-MODY 
(common) 
LOF of β-cell transcription factor; glucosuria 
is common; risk for benign hepatic 
adenomas (rarely can become large and/or 
complicated)  
Excellent glycemic control usually 
possible with low-dose oral 
sulfonylureas 
HNF4A AD: HNF4A-MODY 
(uncommon) 
LOF of β-cell transcription factor; carriers 
may have history of large birth weights 
and/or hyperinsulinemic hypoglycemia 
Often responsive to low-dose oral 
sulfonylureas 
HNF1B AD: HNF1B-MODY 
(uncommon) 
LOF of pancreatic/renal transcription factor; 
renal cysts/genitourinary malformations 
(may be more penetrant than diabetes); 
hypomagnesemia; exocrine pancreatic 
insufficiency, altered liver function tests, 
hyperuricemia, developmental delay (as 
part of chromosome 17q deletion 
syndrome) 
Optimal treatment for diabetes not 
well established; genetic diagnosis 
will inform monitoring and 
management of other features 
ABCC8 AD/AR: ABCC8-NDM 
(common) 
ABCC8-MODY (rare) 
Activating missense mutations in β-cell KATP 
channel SUR1 subunit impair glucose-
stimulated insulin secretion; NDM may have 
spectrum of neurodevelopmental 
dysfunction 
Usually responds to high-dose oral 
sulfonylureas; genetic diagnosis 
facilitates monitoring/intervention 
for neurodevelopmental problems 
KCNJ11 AD: KCNJ11-NDM 
(common) 
KCNJ11-MODY (rare) 
Activating missense mutations in β-cell KATP 
channel Kir6.2 subunit impair glucose 
stimulated insulin secretion; NDM often 
have spectrum of neurodevelopmental 
dysfunction 
Usually responds to high-dose oral 
sulfonylureas; genetic diagnosis 
facilitates monitoring/intervention 




Most common cause of 
transient NDM 
Overexpression of maternally imprinted 
6q24 genes causes impairment of β-cell 
development and function; after remission 
of NDM within first year of life, diabetes will 
often recur in adolescence or adulthood 
Diabetes recurring later in life is 
often responsive to noninsulin 
therapies  
INS AD/AR: INS-NDM 
(common)  
AD: INS-MODY (rare) 
Missense mutations cause insulin protein 
misfolding and progressive β-cell death 
(other mechanisms occur more rarely) 
Early intensive insulin treatment; 
future treatments may feasibly 
target molecular mechanism(s) 
AD, autosomal dominant; AR, autosomal recessive; Kir6.2, inward rectifier potassium channel 6.2; SUR, 
sulfonylurea receptor.  
 
 
